Two injectable candidates have successfully completed clinical trials with strong efficacy and safety results, positioning NIKA for advancement into broader commercialization efforts. The company projects €8.5 Billion revenue from its distribution agreements for Nigeria, Ukraine, UAE, Iraq, Syria, and Jordan. The company combines clinical innovation with a mission-driven approach to global healthcare accessibility.
Cyborg Score Rationale
Nika shows promising clinical data and significant market opportunity in immune-focused therapeutics, but operates as a micro-cap OTC stock with limited visibility, high volatility, and unproven commercial execution. Ambitious revenue projections and a diverse pipeline are offset by execution risk and illiquidity.
Top Insights
Completed clinical trials for two injectable drug candidates targeting multi-billion-dollar disease categories (HIV/AIDS, cancer, autoimmune conditions)
Diversified product portfolio across injectables, oral formulations, and nutraceuticals targeting immune system reinforcement
Ambitious international distribution strategy with €8.5B projected revenue from six emerging markets (Nigeria, Ukraine, UAE, Iraq, Syria, Jordan)
Extreme volatility (190.58% gain in 3 months as of June 2026) characteristic of micro-cap OTC equities with limited institutional coverage
Named Competitors
Immune Therapeutics Division — Large-cap immunology and oncology therapeutics
Regenerative Medicine & Immunology — HIV and hepatitis C treatment portfolio
Dietary Supplements & Nutraceuticals — Competitive immune health and wellness supplements
Recent Developments
(June 2026) Stock volatility spike: 190.58% gain over 3 months and 94.72% gain over 1 month
(May 2022) Name change from Centennial Growth Equities Inc. to Nika Pharmaceuticals, Inc.
(2024) All-time high reached at $13.99 on March 14, 2024, then declined significantly by June 2026 to $0.76
Open the full interactive Nika Pharmaceuticals, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.